watchlist-To The Moon - Tiger Brokers Online Investing Community - To The Moon

1
Comment
Favorite

Chapman Investment inc
04-18

watchlist

INVO BioScience reports Q4 results

INVO BioScience press release : Q4 Revenue of $1.38M misses by $0.55M.Net loss was $(2.0) million, compared to $(2.8) million.Adjusted EBITDA was $(1.2) million, including transaction costs related to the potential merger, compared to $(2.2) million in the prior year.More on INVO BioScience NAYA Biosciences to buy gene therapy company Florida Biotechnologies Seeking Alpha’s Quant Rating on INVO BioScience Historical earnings data for INVO BioScience Financial information for INVO BioScience

INVO BioScience reports Q4 results

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

1

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":296424000430376,"tweetId":"296424000430376","gmtCreate":1713406745986,"gmtModify":1713406931495,"author":{"id":4146275867768112,"authorId":4146275867768112,"authorIdStr":"4146275867768112","name":"Chapman Investment inc","avatar":"https://community-static.tradeup.com/news/efaa44f3e8b9cb60278bee954bf7231a","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.05.02","exceedPercentage":"80.84%","individualDisplayEnabled":0},"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body>watchlist</body></html>","htmlText":"<html><head></head><body>watchlist</body></html>","text":"watchlist","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/296424000430376","repostId":2428894385,"repostType":2,"repost":{"id":"2428894385","pubTimestamp":1713302245,"share":"https://www.laohu8.com/m/news/2428894385?lang=&edition=full","pubTime":"2024-04-17 05:17","market":"fut","language":"en","title":"INVO BioScience reports Q4 results","url":"https://stock-news.laohu8.com/highlight/detail?id=2428894385","media":"seekingalpha","summary":"INVO BioScience press release  : Q4 Revenue of $1.38M   misses by $0.55M.Net loss was $(2.0) million, compared to $(2.8) million.Adjusted EBITDA was $(1.2) million, including transaction costs related to the potential merger, compared to $(2.2) million in the prior year.More on INVO BioScience  NAYA Biosciences to buy gene therapy company Florida Biotechnologies Seeking Alpha’s Quant Rating on INVO BioScience Historical earnings data for INVO BioScience Financial information for INVO BioScience","content":"<html><body><ul>\n<li>INVO BioScience press release  (<span>NASDAQ:INVO</span>): Q4 Revenue of $1.38M (+392.9% Y/Y) <font color=\"red\"> misses by $0.55M</font>.</li>\n<li>Net loss was $(2.0) million, compared to $(2.8) million.</li>\n<li>Adjusted EBITDA was $(1.2) million, including transaction costs related to the potential merger, compared to $(2.2) million in the prior year.</li>\n</ul>\n<div>\n<h2>More on INVO BioScience</h2> <ul> <li>NAYA Biosciences to buy gene therapy company Florida Biotechnologies</li> <li>Seeking Alpha’s Quant Rating on INVO BioScience</li> <li>Historical earnings data for INVO BioScience</li> <li>Financial information for INVO BioScience</li> </ul>\n</div></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INVO BioScience reports Q4 results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINVO BioScience reports Q4 results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-17 05:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4090281-invo-bioscience-reports-q4-results><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>INVO BioScience press release  (NASDAQ:INVO): Q4 Revenue of $1.38M (+392.9% Y/Y)  misses by $0.55M.\nNet loss was $(2.0) million, compared to $(2.8) million.\nAdjusted EBITDA was $(1.2) million, ...</p>\n\n<a href=\"https://seekingalpha.com/news/4090281-invo-bioscience-reports-q4-results\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4082":"医疗保健设备","INVO":"INVO BioScience, Inc."},"source_url":"https://seekingalpha.com/news/4090281-invo-bioscience-reports-q4-results","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2428894385","content_text":"INVO BioScience press release  (NASDAQ:INVO): Q4 Revenue of $1.38M (+392.9% Y/Y)  misses by $0.55M.\nNet loss was $(2.0) million, compared to $(2.8) million.\nAdjusted EBITDA was $(1.2) million, including transaction costs related to the potential merger, compared to $(2.2) million in the prior year.\n\n\nMore on INVO BioScience  NAYA Biosciences to buy gene therapy company Florida Biotechnologies Seeking Alpha’s Quant Rating on INVO BioScience Historical earnings data for INVO BioScience Financial information for INVO BioScience","news_type":1},"isVote":1,"tweetType":1,"viewCount":27,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":9,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}